








Brain Degeneration Risk (BDR) Evaluation
Mild Cognitive Impairment (MCI) is a stage of cognitive decline beyond normal aging but not yet dementia. Early intervention may slow progression, but diagnosing MCI is difficult due to subtle and overlapping symptoms. The BDR system uses an EEG amplifier, a graphical interface, and an AI algorithm to colect and analyze 120 seconds brainwave data via the cloud. It provides objective, quantifiable degeneration probability scores (1-100) that indicates the likelihood of normal aging and mild cognitive impairment (MCI). This can assist physicians in quickly assessing whether a patient is experiencing normal aging, mild cognitive impairment, or has even entered the dementia stage. It can quickly aid physicians in evaluating and determining further resource allocation, whether to refer to a specialist or to order more precise, expensive, and time-consuming tests like MRI.
Mild Cognitive Impairment (MCI) is a stage of cognitive decline beyond normal aging but not yet dementia. Early intervention may slow progression, but diagnosing MCI is difficult due to subtle and overlapping symptoms. The BDR system uses an EEG amplifier, a graphical interface, and an AI algorithm to colect and analyze 120 seconds brainwave data via the cloud. It provides objective, quantifiable degeneration probability scores (1-100) that indicates the likelihood of normal aging and mild cognitive impairment (MCI). This can assist physicians in quickly assessing whether a patient is experiencing normal aging, mild cognitive impairment, or has even entered the dementia stage. It can quickly aid physicians in evaluating and determining further resource allocation, whether to refer to a specialist or to order more precise, expensive, and time-consuming tests like MRI.
Mild Cognitive Impairment (MCI) is a stage of cognitive decline beyond normal aging but not yet dementia. Early intervention may slow progression, but diagnosing MCI is difficult due to subtle and overlapping symptoms. The BDR system uses an EEG amplifier, a graphical interface, and an AI algorithm to colect and analyze 120 seconds brainwave data via the cloud. It provides objective, quantifiable degeneration probability scores (1-100) that indicates the likelihood of normal aging and mild cognitive impairment (MCI). This can assist physicians in quickly assessing whether a patient is experiencing normal aging, mild cognitive impairment, or has even entered the dementia stage. It can quickly aid physicians in evaluating and determining further resource allocation, whether to refer to a specialist or to order more precise, expensive, and time-consuming tests like MRI.
-
AI-based brainwave evaluation, under review by the Taiwan FDA.
Clinically Validated: Collaborated with three major medical centers enrolling 400+ cases and verified the accuracy.
Safe & Convenient: Non-invasive, radiation-free, with an 8-channel electrode system that's easy to use and quick to set up.
Only takes 15 minutes to complete the test and get results immediately.
-
-
HippoScreen
-